A Nasal Spray Could Turn Back The Clock On Brain Aging

What if slowing the mental fog of aging didn’t require surgery or a fistful of pills, but a simple squirt up the nose? A new study in mice found that tiny biological particles, delivered through the nasal passages, can quiet the brain’s inflammatory machinery and improve performance on memory tests in aging animals. It’s early-stage research, but it points toward what could one day become a noninvasive therapy for the kind of forgetfulness and mental sluggishness that creep in with age.

Published in the Journal of Extracellular Vesicles, the research zeroed in on a type of chronic, low-grade brain inflammation scientists have nicknamed “neuroinflammaging.” This isn’t the swelling that flares when you catch a cold. It’s a quiet, persistent burn concentrated in the hippocampus, the brain region responsible for learning and memory. Over time, it damages brain cells, ramps up harmful chemical stress, and disrupts the tiny energy factories inside cells. Researchers increasingly see it as a driving force behind the cognitive decline many people experience as they age.

Led by Ashok K. Shetty at Texas A&M University’s Institute for Regenerative Medicine, the team tested whether delivering microscopic therapeutic packages through the nose could calm that inflammation before it causes lasting harm. Their tool of choice was nano-sized bubbles naturally released by human neural stem cells, packed with molecules thought to help reduce inflammation and support brain cells. Scientists call these bubbles extracellular vesicles, or EVs, tiny packets cells use to send messages and molecular cargo to one another.

How a Nasal Spray for Brain Aging Could Bypass the Brain’s Defenses

Delivering drugs to the brain is notoriously hard because most substances are blocked by the blood-brain barrier, the selective gatekeeper that shields brain tissue. Nasal delivery sidesteps that obstacle. Within six hours of a single dose, labeled EVs were detected across multiple brain regions and taken up by microglia, the brain’s resident immune cells, as well as neurons and other key cell types. Importantly, the treatment did not reduce the total number of microglia, indicating the therapy was reshaping their behavior rather than depleting them.

Testing a Nasal Spray for Brain Aging in Middle-Aged Mice

Researchers used 131 mice, both male and female. Late middle-aged mice at 18 months old, roughly equivalent to a 60-year-old human, received either two nasal doses of EVs or a placebo spaced two weeks apart. A month after the last treatment, the animals underwent memory tests, then their brains were collected for analysis.

Treated mice showed significantly less swelling in brain cells associated with inflammation, and clusters of activated immune cells dropped sharply in both sexes. Chemical damage was measurably lower, while the brain’s own protective defenses were boosted. Genes responsible for cellular energy production increased their activity after treatment, a sign the therapy helped restore the metabolic function that falters in aging brains. On the memory tests, treated animals outperformed untreated peers on two well-established tasks involving object recognition and location, both of which depend on a healthy hippocampus.

Turning Down Two Inflammatory Alarm Systems in the Aging Brain

Two molecular pathways drew particular attention. First, a protein assembly called the NLRP3 inflammasome, essentially a molecular alarm system that floods the area with inflammatory signals when triggered, gets stuck in the “on” position in aging brains. Treated mice showed lower levels of virtually every protein in this chain. Second, the cGAS-STING system, a separate alarm that responds to damaged DNA by generating more inflammation, also became chronically overactive with age. Treated mice showed reduced activity there as well.

To identify which molecules inside the EVs were responsible, researchers engineered versions with one small RNA molecule removed at a time. Removing a molecule called miR-30e-3p caused the EVs to lose most of their ability to suppress the first alarm system. Removing miR-181a-5p left them unable to shut down the second. These two RNA molecules appear to be the active ingredients, not just bystanders.

A genetic analysis of individual brain immune cells, conducted seven days after a single dose, showed treated animals had increased activity in energy-related genes and reduced activity in inflammatory ones. That analysis was based on one male mouse per group, a very small sample that limits how broadly those specific findings can be applied independently, though the pattern aligned with the protein-level results from larger groups.

What Comes Next

None of this means a nasal spray for age-related cognitive decline is close to a pharmacy shelf. This is a mouse study, and therapies that work in rodents frequently fail in people. The optimal dose for aged brains is also unknown, and long-term durability of the effects has not been tested.

Still, the results spanning behavior, cell biology, protein chemistry, and gene-level analysis paint a consistent picture. Rather than broadly suppressing the immune system, the EV therapy appears to selectively reprogram the brain’s own immune cells toward a healthier, more energy-efficient state without reducing their numbers. If the approach eventually translates to humans, a prospect requiring extensive further study, it could offer a different strategy for preserving cognition with age.

---

Disclaimer: This article is based on a preclinical study conducted in mice and does not constitute medical advice. Animal research findings do not always translate to humans. Consult a qualified healthcare provider before making any health-related decisions.

---